Market research
TGTX TG Therapeutics Inc
NASDAQ USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8B
- P/E ratio
- 19.63
- Analyst target
- 69.7143
- Dividend yield
- Not available
- Beta
- 1.8
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 8B
- P/E ratio
- 19.63
- Analyst target
- 69.7143
- Dividend yield
- Not available
- Beta
- 1.8
About
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Research context
TG Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the TGTX discussion.
5 years, 6 months ago
TG Therapeutics, Inc is currently in a long term downtrend where the price is trading 4.4% below its 200 day moving average.
From a valuation standpoint, the stock is 2611.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 36322.5.
TG Therapeutics, Inc's total revenue sank by 0.0% to $38K since the same quarter in the previous year.
Its net income has dropped by 122.9% to $-88M since the same quarter in the previous year.
Finally, its free cash flow fell by 71.5% to $-52M since the same quarter in the previous year.
Based on the above factors, TG Therapeutics, Inc gets an overall score of 0/5.